HMGCR and ovarian carcinoma: The study found that the genetically proxied inhibition of HMG-CoA reductase, which is equivalent to reducing the level of LDL cholesterol by 1 mmol/L, was associated with a 40% lower risk of developing epithelial ovarian cancer (odds ratio, 0.60; 95% confidence interval, 0.43–0.83; p = 0.002), and cases with BRCA1/2 variants also had a 31% lower risk of developing epithelial ovarian cancer (hazard ratio, 0.69; confidence interval, 0.51–0.93; p = 0.01) [29].